Microbiome Therapeutics Market Size, Share and Global Trend By By Application (Diabetes, Inflammatory bowel disorders, Primary Hyperoxyurea, Rheumatoid Arthritis, Clostridium difficile infection (CDI), and Regional Forecast, 2024-2032

In March 2019, AstraZeneca has initiated a research collaboration with Seres Therapeutics to determine the effect of microbiome environment in a patient undergoing immunotherapy for cancer. The microbiome assists in many physiological functions such as metabolic functions, bowel movements, protection against pathogens and many others. The discovery and deeper investigations of the microbiome have now become a cutting-edge advancement in the field of pharmaceuticals. Microbiome therapeutics are designed to re-establish the healthy microbial flora and maintain balance and functionality. Microbiome therapeutics has emerged as the red hot scientific area by grabbing the attention of researchers, investors, and source of new business opportunities and collaborations. 

The huge funding for research and clinical trials for microbiome modulators and a large number of pipeline products are the factors which are projected to drive the global microbiome therapeutics market. The growing awareness about microbiome therapeutics has also encouraged many leading pharmaceutical companies to enter into the global microbiome therapeutics market through mergers and acquisitions. This is likely to become another major factor for the estimated growth in global microbiome therapeutics market.

In 2016, AbbVie Inc. one of the major players of the pharmaceutical industries, partnered with Synlogic for the development of a drug for inflammatory bowel disorders. Another major player in pharmaceutical industries, Bristol-Myers Squibb Company, entered into a research collaboration with Enterome to exploit microbiome drugs potentials in the treatment of immune-oncological indications. Such major mergers and acquisitions are expected to bring a revolution in the pharmaceuticals market dynamics during the forecast period. On the flip side, the stringent government guidelines for the approval of microbiome modulators can be a major factor that is expected to hamper the global microbiome therapeutics. 

Key Players Covered 

Some of the major companies that are involved in the development of microbiome therapeutics are Ritter Pharmaceuticals, AbbVie Inc., Janssen Global Services, LLC, Bristol-Myers Squibb Company, Series Therapeutics, Microbiome Therapeutics LLC., Synthetic Biologics, Inc., Assembly Biosciences Inc., Evelo Biosciences Inc., Fimbrion Therapeutics Inc., ImmuneBiotech, and other players. 

SEGMENTATION 

Within the application segmentation, inflammatory bowel disorder is projected to dominate the global microbiome therapeutics market owing to the rising awareness of the benefits of microbiome therapy in gastrointestinal diseases.

Key Insights

• Pipeline analysis


• Regulatory scenario in key countries


• Key mergers and collaborations


• Technological advancements 

Regional Analysis 

The global microbiome therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The developed countries of North America and Europe are expected to hold the largest share in the microbiome therapeutics market owing to the more focus and investment in research and development of microbiome therapy combined with the strong presence of key market players. The emerging countries of Asia Pacific are anticipated to register higher CAGR in the global microbiome therapeutics market due to the increasing prevalence of diabetes and inflammatory bowel disease that calls for novel therapeutic options which could lead to the rise in demand for microbiome therapeutics.

Key Industry Developments

In October 2017, Finch Therapeutics underwent a definitive merger with Crestovo to form Finch Therapeutics Group to build a pipeline of microbiome therapies.

In April 2019, Holobiome announced the company’s collaboration with Johnson & Johnson Consumer Inc. focusing research on proprietary bacterial consortia for the treatment of digestive diseases.

In May 2019, Vedanta Biosciences announced that the company’s key microbiome patent was upheld in the European opposition proceedings strengthening the company’s IP rights on microbiome therapeutics.